摘要
目的:对我院利奈唑胺血药浓度监测结果进行分析,探讨利奈唑胺血药浓度的影响因素。方法:回顾性收集2019年2月~2020年6月我院符合纳入标准住院患者的相关信息,采用单因素及多因素回归分析利奈唑胺血药谷浓度的影响因素。结果:73例患者中利奈唑胺平均血药谷浓度为(6.54±2.31)μg·ml^(-1),在参考范围内的占34.2%,低于参考范围的占12.3%,高于参考范围的占53.4%;单因素分析结果显示老年患者和肾功能不全患者利奈唑胺血药谷浓度高于非老年患者及肾功能正常患者(P<0.05);多因素分析结果显示利奈唑胺谷浓度随ALT和肌酐清除率的升高而降低。结论:利奈唑胺血药浓度个体差异大,肾功能不全患者进行血药浓度监测可能有助于降低不良反应发生风险。
Objective: To analyze plasma concentrations of linezolid and explore the influence factors. Methods: The clinical data of inpatients who met inclusion and exclusion criteria between February 2019 and June 2020 were collected. Single and multiple factor regression analyses were used to analyze the influencing factors in plasma valley concentration of linezolid. Results: The mean serum valley concentration of linezolid was(6.54±2.31) μg·mlin^(-1) 73 patients, and 12.3% of patients were lower than the reference range, while 53.4% experienced overexposure. Single factor analysis results showed that the plasma valley concentration of linezolid in elderly or with renal dysfunction patients was significantly higher than that in non-elderly or with normal renal function patients(P<0.05). Multivariate factor analysis results showed that the valley concentration of linezolid decreased with the increase of ALT and creatinine clearance. Conclusion: The plasma concentration of linezolid varies greatly among individuals, and monitoring plasma concentration in patients with renal insufficiency may be helpful to reduce the risks of adverse reactions.
作者
李娟
张峻
王晶晶
王茜
冯朴琼
何瑾
Li Juan;Zhang Jun;Wang Jingjing;Wang Xi;Feng Puqiong;He Jin(Department of Clinical Pharmacy,First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)
出处
《中国药师》
CAS
2022年第8期1406-1409,共4页
China Pharmacist
基金
云南省基础研究计划(昆明医科大学联合专项)项目(编号:202101AY070001-091)
云南省高层次卫生计生技术人才培养专项经费资助项目(编号:D-2018042)。
关键词
利奈唑胺
血药谷浓度
影响因素
肌酐清除率
Linezolid
Plasma valley concentration
Influencing factors
Creatinine clearance
